Literature DB >> 32391668

[Dynamic inflammatory response in a critically ill COVID-19 patient treated with corticosteroids].

Sheng Zhagn1, Danping Li2, Huazhong Chen3, Dan Zheng1, Yiping Zhou1, Baoguo Chen4, Weiwu Shi4, Ronghai Lin1.   

Abstract

OBJECTIVE: To investigate the effect of corticosteroids therapy on the inflammatory response in a critically ill coronavirus disease 2019 (COVID-19) patient.
METHODS: A 55-year old female patient with critical ill COVID-19 was admitted in Taizhou Hospital on January 19, 2020. The patient was treated with methylprednisolone 80 mg on the 2nd day after admission. Thereafter, the dose was adjusted in a timely manner and the therapy lasted for 13 days. The peripheral lymphocyte subsets (CD3+T, CD4+ T, CD8+ T, NK cells, B cells), as well as serum levels of lymphocyte factors (IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ) were dynamically monitored.
RESULTS: On D1 of admission, the numbers of peripheral blood CD3+ T, CD4+ T, CD8+ T, and NK cells were significantly lower than the normal range. With the improvement of the disease, the numbers of CD3+ T, CD8+ T and CD4 + T cells gradually recovered and showed a linear growth trend (linear fitting equation: Y=18.59X+109.4, P<0.05). On D2 of admission, the patient's IL-6 and IL-10 levels were significantly higher than normal values, IFN-γ was at a normal high value, and then rapidly decreased; IL-2, IL-4, and TNF-α were all in the normal range. On the D6 and D7, the IL-6 and IL-10 decreased to the normal range for the first time. On the D18, the sputum virus nucleic acid test was negative for the first time, and the fecal virus nucleic acid test was still positive; on the D20 the sputum and fecal virus nucleic acid test were both negative. On D34, the patient recovered and was discharged. At the discharge the muscle strength score of the patient was 44 and the daily life ability evaluation was 90.
CONCLUSIONS: In the absence of effective antiviral drugs, early use of appropriate doses of corticosteroids in critically ill patient with COVID-19 can quickly alleviate inflammatory response and improve clinical symptoms, however, it may reduce the number of T cells, and to adjust the dose in time is necessary.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32391668      PMCID: PMC8800790          DOI: 10.3785/j.issn.1008-9292.2020.03.10

Source DB:  PubMed          Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban        ISSN: 1008-9292


  10 in total

Review 1.  Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients' data from four randomized trials and trial-level meta-analysis of the updated literature.

Authors:  G Umberto Meduri; Lisa Bridges; Mei-Chiung Shih; Paul E Marik; Reed A C Siemieniuk; Mehmet Kocak
Journal:  Intensive Care Med       Date:  2015-10-27       Impact factor: 17.440

2.  [A study of pulmonary inflammatory reaction induced by N-protein of SARS-CoV in rat models and effects of glucocorticoids on it].

Authors:  Dong Hao; Li-xian He; Jie-ming Qu; Jue Pan; Bi-jie Hu; Jing Zhang; Zhuo-zhe Li
Journal:  Zhonghua Nei Ke Za Zhi       Date:  2005-12

Review 3.  The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance.

Authors:  Ellen L Burnham; William J Janssen; David W H Riches; Marc Moss; Gregory P Downey
Journal:  Eur Respir J       Date:  2013-03-21       Impact factor: 16.671

4.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

5.  Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.

Authors:  Xiaobo Yang; Yuan Yu; Jiqian Xu; Huaqing Shu; Jia'an Xia; Hong Liu; Yongran Wu; Lu Zhang; Zhui Yu; Minghao Fang; Ting Yu; Yaxin Wang; Shangwen Pan; Xiaojing Zou; Shiying Yuan; You Shang
Journal:  Lancet Respir Med       Date:  2020-02-24       Impact factor: 30.700

6.  MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile.

Authors:  Waleed H Mahallawi; Omar F Khabour; Qibo Zhang; Hatim M Makhdoum; Bandar A Suliman
Journal:  Cytokine       Date:  2018-02-02       Impact factor: 3.861

Review 7.  Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology.

Authors:  Rudragouda Channappanavar; Stanley Perlman
Journal:  Semin Immunopathol       Date:  2017-05-02       Impact factor: 9.623

8.  Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome.

Authors:  C K Wong; C W K Lam; A K L Wu; W K Ip; N L S Lee; I H S Chan; L C W Lit; D S C Hui; M H M Chan; S S C Chung; J J Y Sung
Journal:  Clin Exp Immunol       Date:  2004-04       Impact factor: 4.330

9.  Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.

Authors:  Clark D Russell; Jonathan E Millar; J Kenneth Baillie
Journal:  Lancet       Date:  2020-02-07       Impact factor: 79.321

10.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome.

Authors:  Zhe Xu; Lei Shi; Yijin Wang; Jiyuan Zhang; Lei Huang; Chao Zhang; Shuhong Liu; Peng Zhao; Hongxia Liu; Li Zhu; Yanhong Tai; Changqing Bai; Tingting Gao; Jinwen Song; Peng Xia; Jinghui Dong; Jingmin Zhao; Fu-Sheng Wang
Journal:  Lancet Respir Med       Date:  2020-02-18       Impact factor: 30.700

  10 in total
  2 in total

1.  Efficacy and Safety of Corticosteroid Treatment in Patients With COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Wenwen Cheng; Yufeng Li; Liyan Cui; Ying Chen; Sharui Shan; Duan Xiao; Xiaoyun Chen; Zhuoming Chen; Anding Xu
Journal:  Front Pharmacol       Date:  2020-09-09       Impact factor: 5.810

2.  Authors' response to the Letter to the Editor regarding: Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations.

Authors:  Gennaro D'Amato; Luca Acanfora; Lucrezia Delli Paoli; Maria D'Amato
Journal:  Multidiscip Respir Med       Date:  2021-04-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.